Pharmaceutical Innovation

Huffington Post

Moving in the Right Direction on Intellectual Property Protection

Focusing only on the cost increases associated with stronger (but still lagging) intellectual property protection for pharmaceutical innovators is simplistic and wrong. It is the balance of these costs and benefits that are the ultimate determinant of whether or not Canadians are better off, not just the post-2023 increase in drug costs to provincial governments, patients, and insurers.

Making Drug Regulation Smarter Will Save Canadian Lives

Canadian regulations clearly restrict access to new medical innovations by placing a general ban on their use until Health Canada completes duplicate reviews already undertaken (earlier and faster) by regulators in Europe and the U.S. Regulators in these jurisdictions bear responsibility for the health and safety of populations that dwarf Canada's population of less than 35 million. Canada's current approach imposes considerable delays on Canadians struggling with illness. A closer look suggests the delays did much more than cause needless discomfort.